GNTA - סך החוב של החברה Genenta

The debt history of Genenta Science S.p.A. (GNTA) demonstrates a financial burden where the value of 0.01 expresses the metric level. Patents for stem cell modification and colossal R&D expenditures create insurmountable barriers for competitors. Professional European management ensures transparent reporting, yet the novelty of gene therapy and strict regulatory oversight pose serious risks to capital.

This metric aggregates all external and internal borrowings, allowing for an assessment of financial stability and the risk of liquidity shortages. For Genenta Science S.p.A. (GNTA), this parameter is critical, as financing the development of tumor gene therapy methods requires significant capital expenditures prior to commercialization, which is clearly reflected in the changing debt load.